Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Protgen Ltd. is a research and development-oriented high-tech enterprise founded by returned overseas students. It is an important component of the National Engineering Laboratory for Anti-Tumor Protein Drugs and undertakes the industrial transformation of scientific research projects. The company has long been strongly supported by the National Development and Reform Commission, the Ministry of Science and Technology, Beijing, Yantai City of Shandong Province and Shenzhen City of Guangdong Province. The company is committed to the development of recombinant protein drugs, antibody drugs and in vitro diagnostic reagents with independent intellectual property rights and international competitiveness. It has established four subsidiaries in Beijing, Yantai City, Shandong Province and Shenzhen City, Guangdong Province, respectively. The project's industrialization implementation task has established a mature R&D and industrialization base, and has a series of internationally leading core proprietary technologies in protein drug preparation. The company's research and management team has a rich experience in successfully researching and developing national Class I new drugs and national Class III in vitro diagnostic reagents, and established a mature recombinant protein drug scale preparation technology platform and in vitro diagnostic kit development technology platform, in the research and development of recombinant protein drugs. Management, industrialization and other fields have rich practical experience. During the "10th Five-Year Plan" to the "Twelfth Five-Year Plan" period, Proji has successively presided over one national 863 project, three "major new drug creation" projects, five provincial and ministerial research projects, and two national 863 projects. There are 4 topics in the creation of new drugs. The company has cooperated with Tsinghua University for 12 years, and has established a highly efficient and increasingly mature technology for rapid transformation of biotechnology results in production, learning, research and use. It has obtained 58 invention patents, including 17 domestic and 41 foreign countries.

NIPD Genetics Ltd., a subsidiary of Medicover AB, is a company headquartered in Nicosia, Cyprus, that operates as biotechnology company. The firm was founded in 2010 by Philippos C. Patsalis, who is currently the CEO of the firm. Medicover AB acquired NIPD Genetics Ltd. on January 18, 2022 for $50.32 million.

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database. Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.

F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom.

Ibex Biosciences engages in a diverse approach to research and development. Ibex strives to discover, validate, and produce potential solutions to a multitude of serious challenges facing human and ecological health by investing in exploratory projects and processes that may not have been validated within the public research community. The company develops therapeutic antibodies, gene therapy, and stem cell programs intended to address unmet medical conditions plaguing humanity. Its robust portfolio focuses on three primary areas: (1) cancer and non-cancer therapeutic antibodies/intrabody: Ibex is producing and developing antibodies targeting multiple cancers including breast, prostate, glioblastoma, lung, and neuroblastoma; (2) Cancer Gene Therapy: Ibex is developing a gene therapy that targets multiple cancer cells in-vitro including glioblastoma, melanoma, and cervical; and (3) Diagnostic Antibodies: Ibex is developing a skin cancer initial diagnostic, a CIN (Cervical Intraepithelial Neoplasia) diagnostic, and an early-stage pancreatic cancer diagnostic. It was founded in 2015 and is headquartered in Cumberland, Maryland.

Traxxsson is a biotechnology company that develops diagnostics for cancer using protein biomarkers. It uses a proprietary panel of biomarkers to identify at-risk patients who have questionable radiology images. It has three tests: PRO CancSure to identify prostate cancer patients in need of aggressive treatment, BRE CancSure to confirm the presence of breast cancer in women with positive mammograms, and LNG CancSure to confirm the presence of lung cancer in patients with positive low-density CAT scan results. The company was founded in 2009 and is based in St. Louis, Missouri.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Yantai Progi Biotechnology Development Co., Ltd., established on 2009-12-09, Business scope includes licensed projects:Production of Class III Medical Devices;Class III medical device business;pharmaceutical production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Disinfectant production(Free of Hazardous Chemicals);Production of protective equipment for medical personnel(Class II medical device);Production of medical masks;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Disinfectant sales(Free of Hazardous Chemicals);Development of Human Gene Diagnosis and Therapy Technology;Human stem cell technology development and application;R&D and application of cell technology;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of protective equipment for medical personnel(Ι class medical device);Wholesale of protective equipment for medical staff;Wholesale medical masks;Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Syntekabio is a Korean biotech firm, developing personal genome map which is expected to enable personalized medical service. The company also provides a technology for collecting and integrating decrypted whole genome data.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Cytyc Corporation, a diagnostic and medical device company, designs, develops, manufactures, and markets and diagnostic and surgical products. The company offers its products for a range of cancer and women's health applications, such as cervical cancer screening, menstrual bleeding treatment, early-stage breast cancer radiation treatment, and malignant brain tumors radiation treatment applications. It serves customers in the Canadian, European, and Asia/Pacific markets. The company was founded in 1987 and is based in Marlborough, Massachusetts. As of October 22, 2007, CYTYC Corporation opeartes as a subsidiary of Hologic Inc.